Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening

Award Number: R43DK121580
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2019
PERIOD OF PERFORMANCE END DATE: 01/31/2020

Group Awards By:

View Award Description

Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening - The human intestine is a remarkable organ which stores 90% of the body’s important neurotransmitter, serotonin, in enteroendocrine cells (EECs). Serotonin and other EECs-secreted hormones play critical roles in regulating human feeding behavior and satiety, and their dysregulation leads to overeating and a host of other diseases. For these reasons, there is a need in the therapeutics marketplace for in vitro intestinal EECs platform that precisely recapitulates the physiology of in vivo intestines. To meet this need, Altis Biosystems Inc., an early stage biotechnology company, will collaborate with scientists at the University of North Carolina at Chapel Hill to develop a novel, primary-stem-cells-based, in vitro intestinal model (termed RepliGut) that contains sufficient EECs for studying serotonin secretion. The platform will be designed with the eventual goal during Phase II of creating systems for assaying a variety of intestinal hormones in a high-content screening. The goal is to validate the RepliGut product and bring this technology to therapeutics market. The collaboration represents an ideal opportunity for the translation of an academic technology to the marketplace through the NIH sponsored SBIR program. In this Phase I SBIR, this collaboration will optimize the RepliGut 96- well platform for EECs cell lineage allocation, investigate cell variation, quantify serotonin secretion, and validate the platform with a small-scale compound screen for serotonin.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $223,049 )
2019	2019	ALTIS BIOSYSTEMS, INC.	1289 N FORDHAM BLVD STE A234	CHAPEL HILL	NC	27514	ORANGE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/23/2019	NEW	$223,049
														Subtotal = $223,049

Grand Total All Awards = $223,049

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening

Award Number: R43DK121580

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2019

PERIOD OF PERFORMANCE END DATE: 01/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer